News

Neutral GlaxoSmithKline Pharmaceuticals Ltd For Target Rs.2,800 By Motilal Oswal Financial Services Ltd Industry headwinds hurt performance of generic medicines * Glaxo Pharma (GLXO) delivered better-than-expected 2QFY25 performance. The robust growth in the specialty and pediatric vaccine segments was offset by headwinds in the generic medicine segment. * We raise our estimates by 4%/5%/4% for FY25/FY26/FY27 to factor in: 1) new launches in the oncology segment, b) superior show in the specialty segment, and c) better operating leverage. We value GLXO at 46x 12M forward earning...
Neutral GlaxoSmithKline Pharmaceuticals Ltd For Target Rs.2,800 By Motilal Oswal Financial Services Ltd
Neutral GlaxoSmithKline Pharmaceuticals Ltd For Target Rs.2,800 By Motilal Oswal Financial Services Ltd
Source: Motilal Oswal Financial Services Ltd
2024-11-13 03:37:29 pm
India`s GlaxoSmithKline Pharma posts higher Q2 profit on strong demand India's GlaxoSmithKline Pharmaceuticals reported a higher second-quarter adjusted profit on Tuesday, driven by strong demand for its generic drugs and vaccines. The Indian unit of British drugmaker GSK said its consolidated profit before tax rose to 3.44 billion rupees ($41 million) in the July-September quarter, from 2.99 billion rupees year ago. The latest quarter included a 46.9-million-rupee gain on the sale of some residential properties. Its revenue from operations climbed ...
India`s GlaxoSmithKline Pharma posts higher Q2 profit on strong demand
India`s GlaxoSmithKline Pharma posts higher Q2 profit on strong demand
Source: Reuters
2024-10-29 05:26:09 pm
India's GlaxoSmithKline Pharma posts higher Q1 adjusted profit on strong demand India's GlaxoSmithKline Pharmaceuticals reported a higher first-quarter adjusted profit on Friday, driven by strong demand for its generic drugs and vaccines. The Indian unit of British drugmaker GSK reported a consolidated profit before tax and exceptional items of 2.49 billion rupees ($29.7 million) for the quarter ended June 30, compared with a profit of 1.64 billion rupees year ago. The company had a one-time gain from the sale of surplus residential properties worth 173 million...
India's GlaxoSmithKline Pharma posts higher Q1 adjusted profit on strong demand
India's GlaxoSmithKline Pharma posts higher Q1 adjusted profit on strong demand
Source: Reuters
2024-08-02 04:25:32 pm
Neutral GlaxoSmithKline Pharma Ltd Fo Target Rs.2,380 By Motilal Oswal Financial Services Business in recovery mode! Valuation adequately factors in the earnings upside * GlaxoSmithKline Pharma (GLXO), a domestic-focused player, reported a moderate revenue/EBITDA/PAT growth of 3%/10%/14% over FY18-23. * In FY24, GLXO exhibited a healthy pick-up with 6.2%/13.0%/20.5% YoY growth in revenue/EBITDA/PAT, fueled by increased NLEM-based product volumes, takeoff of its vaccines business (from 3QFY24), and traction in new launches. * Considering an 8% earnings CAGR and a stabilizi...
Neutral GlaxoSmithKline Pharma Ltd Fo Target Rs.2,380 By Motilal Oswal Financial Services
Neutral GlaxoSmithKline Pharma Ltd Fo Target Rs.2,380 By Motilal Oswal Financial Services
Source: Motilal Oswal Financial Services
2024-07-11 10:56:49 am
GSK India arm`s Q3 profit falls on government price cap GlaxoSmithKline Pharmaceuticals, the Indian unit of the UK's GSK, reported a 3% fall in third-quarter profit on Monday, hurt by the government's pricing cap on certain medicines. Consolidated profit before exceptional items and tax for the quarter ended Dec. 31 was 2.29 billion rupees ($27.6 million), compared with 2.36 billion rupees a year earlier. GlaxoSmithKline, which derives most of its revenue from India, continued to grapple with challenges following the inclusion of its...
GSK India arm`s Q3 profit falls on government price cap
GSK India arm`s Q3 profit falls on government price cap
Source: Reuters
2024-02-13 09:44:53 am
Strides Pharma Science rises as its arm receives USFDA`s approval for Pregabalin Capsules Strides Pharma Science is currently trading at Rs. 694.00, up by 8.25 points or 1.20% from its previous closing of Rs. 685.75 on the BSE. The scrip opened at Rs. 695.50 and has touched a high and low of Rs. 695.50 and Rs. 686.30 respectively. So far 262 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 10 has touched a 52 week high of Rs. 735.20 on 05-Jan-2024 and a 52 week low of Rs. 268.40 on 21-Mar-2023. Last one week high and low of the scrip st...
Strides Pharma Science rises as its arm receives USFDA`s approval for Pregabalin Capsules
Strides Pharma Science rises as its arm receives USFDA`s approval for Pregabalin Capsules
Source: Accord Fintech
2024-01-29 10:05:21 am